MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwired - August 10, 2013) - MorphoSys AG /
MorphoSys Closes on the Alliance with Celgene for MOR202 and Increases
Ad hoc announcement according to § 15 WpHG.
Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Celgene Acquires 3.4 % Equity Stake via a Capital Increase
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today
announced that its MOR202 alliance with Celgene Corporation has become
upon receiving anti-trust clearance under the US Hart-Scott-Rodino Act. In
conjunction with deal closure, MorphoSys increased its financial guidance
fiscal year 2013 and the management board and supervisory board of
resolved on a capital increase from authorized capital to issue 797,150 new
shares to Celgene Alpine Investment Co., LLC.
Jens Holstein, Chief Financial Officer of MorphoSys AG, commented: "We are
pleased about receiving regulatory clearance and will now put our strategic
alliance with Celgene into action. The upfront payment plus the equity
strengthens our financial position, enabling us to expand our proprietary
portfolio of promising development candidates through targeted
As a result of the Celgene transaction, MorphoSys has increased its
guidance for fiscal year 2013. MorphoSys now expects revenues of
EUR 74 million to EUR 78 million (previously EUR 68 million to EUR 72
and an EBIT of EUR 2 million to EUR 6 million (previously EUR -2 million to
In the capital increase Celgene will invest EUR 46.2 million to subscribe
797,150 new shares of MorphoSys at a share price of EUR 57.90 per share.
represents 3.4 % of MorphoSys's registered share capital and a premium of
on the share's closing price on August 9, 2013.
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the treatment
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,
RapMAT®, arYla®, Ylanthia®
and 100 billion high potentials® are registered trademarks of
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a
of MorphoSys AG.
This communication contains certain forward-looking statements concerning
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements
far as the wording of the relevant press release is concerned.
Media Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE